By Michele Maatouk
Date: Tuesday 06 Jan 2026
(Sharecast News) - US biotech firm Amgen said on Tuesday that it has bought Dark Blue Therapeutics, a UK biotechnology company specialising in cancer treatments, for up to $840m.
| SEP cashes in as US giant Amgen buys cancer drug... | 26-Jan-2011 | The Scotsman |
| Amgen Buys a Cancer Drug Maker | 25-Jan-2011 | New York Times |
| Tech Ticker | 16-Dec-2010 | BayArea.com |
| Amgen drug delayed spread of prostate cancer to ... | 15-Dec-2010 | LA Times |
| Business Briefing | 24-Dec-2009 | LA Times |
| Currency | US Dollars |
| Share Price | $ 373.94 |
| Change Today | $ -1.56 |
| % Change | -0.42 % |
| 52 Week High | $384.32 |
| 52 Week Low | $262.28 |
| Volume | 1,734,854 |
| Shares Issued | 538.80m |
| Market Cap | $201,479m |
| Beta | 0.01 |
| RiskGrade | 100 |
| Strong Buy | 7 |
| Buy | 8 |
| Neutral | 14 |
| Sell | 2 |
| Strong Sell | 1 |
| Total | 32 |

| Time | Volume / Share Price |
| 15:11 | 40 @ $373.94 |
| 15:11 | 61 @ $373.94 |
| 15:11 | 49 @ $373.94 |
| 15:10 | 40 @ $373.94 |
| 15:10 | 50 @ $373.94 |
You are here: research